Drug Profile
Research programme: chlamydia vaccines - Abera Bioscience
Alternative Names: Ab 03 - Abera BioscienceLatest Information Update: 20 Jun 2023
Price :
$50
*
At a glance
- Originator Abera Bioscience AB
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Chlamydial infections
Most Recent Events
- 20 Jun 2023 Preclinical trials in Chlamydial infections (Prevention) in Sweden (unspecified route) (Abera Bioscience pipeline, June 2023)
- 04 Jul 2016 Research programme: chlamydia vaccines - Abera Bioscience is available for licensing as of 04 Jul 2016. http://aberabio.com/partnering-licensing/
- 04 Jul 2016 Early research in Chlamydial infections (Prevention) in Sweden (unspecified route)